Research ExplorerPublicationsHigh-resolution analysis of individual spike peptide-specifi...

High-resolution analysis of individual spike peptide-specific CD4+ T-cell responses in vaccine recipients and COVID-19 patients

Standard

High-resolution analysis of individual spike peptide-specific CD4+ T-cell responses in vaccine recipients and COVID-19 patients. / Karsten, Hendrik; Cords, Leon; Westphal, Tim; Knapp, Maximilian; Brehm, Thomas Theo; Hermanussen, Lennart; Omansen, Till Frederik; Schmiedel, Stefan; Woost, Robin; Ditt, Vanessa; Peine, Sven; Lütgehetmann, Marc; Huber, Samuel; Ackermann, Christin; Wittner, Melanie; Addo, Marylyn Martina; Sette, Alessandro; Sidney, John; Schulze Zur Wiesch, Julian.

In: CLIN TRANSL IMMUNOL, Vol. 11, No. 8, e1410, 2022.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Karsten, H, Cords, L, Westphal, T, Knapp, M, Brehm, TT, Hermanussen, L, Omansen, TF, Schmiedel, S, Woost, R, Ditt, V, Peine, S, Lütgehetmann, M, Huber, S, Ackermann, C, Wittner, M, Addo, MM, Sette, A, Sidney, J & Schulze Zur Wiesch, J 2022, 'High-resolution analysis of individual spike peptide-specific CD4+ T-cell responses in vaccine recipients and COVID-19 patients', CLIN TRANSL IMMUNOL, vol. 11, no. 8, e1410. https://doi.org/10.1002/cti2.1410

APA

Karsten, H., Cords, L., Westphal, T., Knapp, M., Brehm, T. T., Hermanussen, L., Omansen, T. F., Schmiedel, S., Woost, R., Ditt, V., Peine, S., Lütgehetmann, M., Huber, S., Ackermann, C., Wittner, M., Addo, M. M., Sette, A., Sidney, J., & Schulze Zur Wiesch, J. (2022). High-resolution analysis of individual spike peptide-specific CD4+ T-cell responses in vaccine recipients and COVID-19 patients. CLIN TRANSL IMMUNOL, 11(8), [e1410]. https://doi.org/10.1002/cti2.1410

Vancouver

Karsten H, Cords L, Westphal T, Knapp M, Brehm TT, Hermanussen L et al. High-resolution analysis of individual spike peptide-specific CD4+ T-cell responses in vaccine recipients and COVID-19 patients. CLIN TRANSL IMMUNOL. 2022;11(8). e1410. https://doi.org/10.1002/cti2.1410

Bibtex

@article{92953303eabf4e98a33600d949738a84,
title = "High-resolution analysis of individual spike peptide-specific CD4+ T-cell responses in vaccine recipients and COVID-19 patients",
abstract = "Objectives: Potential differences in the breadth, distribution and magnitude of CD4+ T-cell responses directed against the SARS-CoV-2 spike glycoprotein between vaccinees, COVID-19 patients and subjects who experienced both ways of immunisation have not been comprehensively compared on a peptide level.Methods: Following virus-specific in vitro cultivation, we determined the T-cell responses directed against 253 individual overlapping 15-mer peptides covering the entire SARS-CoV-2 spike glycoprotein using IFN-γ ELISpot and intracellular cytokine staining. In vitro HLA binding was determined for selected peptides.Results: We mapped 955 single peptide-specific CD4+ T-cell responses in a cohort of COVID-19 patients (n = 8), uninfected vaccinees (n = 16) and individuals who experienced both infection and vaccination (n = 11). Patients and vaccinees (two-time and three-time vaccinees alike) had a comparable number of CD4+ T-cell responses (median 26 vs. 29, P = 0.7289). Most of these specificities were conserved in B.1.1.529 and the BA.4 and BA.5 sublineages. The highest magnitude of these in vitro IFN-γ CD4+ T-cell responses was observed in COVID-19 patients (median 0.35%), and three-time vaccinees showed a higher magnitude than two-time vaccinees (median 0.091% vs. 0.175%, P < 0.0001). Twelve peptide specificities were each detected in at least 40% of subjects. In vitro HLA binding showed promiscuous presentation by DRB1 molecules for several peptides.Conclusion: Both SARS-CoV-2 infection and vaccination prime broadly directed T-cell responses directed against the SARS-CoV-2 spike glycoprotein. This comprehensive high-resolution analysis of spike peptide specificities will be a useful resource for further investigation of spike-specific T-cell responses.",
author = "Hendrik Karsten and Leon Cords and Tim Westphal and Maximilian Knapp and Brehm, {Thomas Theo} and Lennart Hermanussen and Omansen, {Till Frederik} and Stefan Schmiedel and Robin Woost and Vanessa Ditt and Sven Peine and Marc L{\"u}tgehetmann and Samuel Huber and Christin Ackermann and Melanie Wittner and Addo, {Marylyn Martina} and Alessandro Sette and John Sidney and {Schulze Zur Wiesch}, Julian",
note = "{\textcopyright} 2022 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.",
year = "2022",
doi = "10.1002/cti2.1410",
language = "English",
volume = "11",
journal = "CLIN TRANSL IMMUNOL",
issn = "2050-0068",
publisher = "John Wiley & Sons Inc.",
number = "8",

}

RIS

TY - JOUR

T1 - High-resolution analysis of individual spike peptide-specific CD4+ T-cell responses in vaccine recipients and COVID-19 patients

AU - Karsten, Hendrik

AU - Cords, Leon

AU - Westphal, Tim

AU - Knapp, Maximilian

AU - Brehm, Thomas Theo

AU - Hermanussen, Lennart

AU - Omansen, Till Frederik

AU - Schmiedel, Stefan

AU - Woost, Robin

AU - Ditt, Vanessa

AU - Peine, Sven

AU - Lütgehetmann, Marc

AU - Huber, Samuel

AU - Ackermann, Christin

AU - Wittner, Melanie

AU - Addo, Marylyn Martina

AU - Sette, Alessandro

AU - Sidney, John

AU - Schulze Zur Wiesch, Julian

N1 - © 2022 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.

PY - 2022

Y1 - 2022

N2 - Objectives: Potential differences in the breadth, distribution and magnitude of CD4+ T-cell responses directed against the SARS-CoV-2 spike glycoprotein between vaccinees, COVID-19 patients and subjects who experienced both ways of immunisation have not been comprehensively compared on a peptide level.Methods: Following virus-specific in vitro cultivation, we determined the T-cell responses directed against 253 individual overlapping 15-mer peptides covering the entire SARS-CoV-2 spike glycoprotein using IFN-γ ELISpot and intracellular cytokine staining. In vitro HLA binding was determined for selected peptides.Results: We mapped 955 single peptide-specific CD4+ T-cell responses in a cohort of COVID-19 patients (n = 8), uninfected vaccinees (n = 16) and individuals who experienced both infection and vaccination (n = 11). Patients and vaccinees (two-time and three-time vaccinees alike) had a comparable number of CD4+ T-cell responses (median 26 vs. 29, P = 0.7289). Most of these specificities were conserved in B.1.1.529 and the BA.4 and BA.5 sublineages. The highest magnitude of these in vitro IFN-γ CD4+ T-cell responses was observed in COVID-19 patients (median 0.35%), and three-time vaccinees showed a higher magnitude than two-time vaccinees (median 0.091% vs. 0.175%, P < 0.0001). Twelve peptide specificities were each detected in at least 40% of subjects. In vitro HLA binding showed promiscuous presentation by DRB1 molecules for several peptides.Conclusion: Both SARS-CoV-2 infection and vaccination prime broadly directed T-cell responses directed against the SARS-CoV-2 spike glycoprotein. This comprehensive high-resolution analysis of spike peptide specificities will be a useful resource for further investigation of spike-specific T-cell responses.

AB - Objectives: Potential differences in the breadth, distribution and magnitude of CD4+ T-cell responses directed against the SARS-CoV-2 spike glycoprotein between vaccinees, COVID-19 patients and subjects who experienced both ways of immunisation have not been comprehensively compared on a peptide level.Methods: Following virus-specific in vitro cultivation, we determined the T-cell responses directed against 253 individual overlapping 15-mer peptides covering the entire SARS-CoV-2 spike glycoprotein using IFN-γ ELISpot and intracellular cytokine staining. In vitro HLA binding was determined for selected peptides.Results: We mapped 955 single peptide-specific CD4+ T-cell responses in a cohort of COVID-19 patients (n = 8), uninfected vaccinees (n = 16) and individuals who experienced both infection and vaccination (n = 11). Patients and vaccinees (two-time and three-time vaccinees alike) had a comparable number of CD4+ T-cell responses (median 26 vs. 29, P = 0.7289). Most of these specificities were conserved in B.1.1.529 and the BA.4 and BA.5 sublineages. The highest magnitude of these in vitro IFN-γ CD4+ T-cell responses was observed in COVID-19 patients (median 0.35%), and three-time vaccinees showed a higher magnitude than two-time vaccinees (median 0.091% vs. 0.175%, P < 0.0001). Twelve peptide specificities were each detected in at least 40% of subjects. In vitro HLA binding showed promiscuous presentation by DRB1 molecules for several peptides.Conclusion: Both SARS-CoV-2 infection and vaccination prime broadly directed T-cell responses directed against the SARS-CoV-2 spike glycoprotein. This comprehensive high-resolution analysis of spike peptide specificities will be a useful resource for further investigation of spike-specific T-cell responses.

U2 - 10.1002/cti2.1410

DO - 10.1002/cti2.1410

M3 - SCORING: Journal article

C2 - 35957961

VL - 11

JO - CLIN TRANSL IMMUNOL

JF - CLIN TRANSL IMMUNOL

SN - 2050-0068

IS - 8

M1 - e1410

ER -